{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"GN in Ten","title":"BRB 8: Secondary FSGS","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/38a60162\"></iframe>","width":"100%","height":180,"duration":1070,"description":"In this \"Board Review Bonus\" (BRB) episode, hosts Dr. Kenar Jhaveri and Dr. Koyal Jain break down the essential \"must-knows\" for Secondary Focal Segmental Glomerulosclerosis (FSGS). Geared toward board preparation and clinical practice, this bite-sized session covers everything from distinguishing secondary lesions from primary disease to navigating the modern cardiorenal toolkit.\n\nKey Discussion Points\nPrimary vs. Secondary Differentiation: Primary FSGS typically presents with full-blown nephrotic syndrome (heavy proteinuria, hypoalbuminemia, edema) and diffuse foot process effacement (>80%). Secondary FSGS usually manifests with indolent nephrotic-range proteinuria, normal serum albumin, and focal or mild foot process effacement.\nDecoding Biopsy Variants & Pathology: While Columbia classification variants (perihilar, tip, cellular, collapsing, NOS) are not strictly diagnostic on their own, specific patterns offer critical clues:Perihilar & Glomerulomegaly: Point toward maladaptive, high-flow hyperfiltration states.\nCollapsing Variant: Prompts a rigorous search for viral triggers (HIV, COVID-19) or drug-induced etiologies driven by high local interferon activity.\nThe \"Global\" Trap: Always distinguish true FSGS from secondary focal global glomerular sclerosis, which represents end-stage scarring rather than a primary podocytopathy.\nPathogenesis: A mismatch between nephron mass and body mass causes glomerular hypertrophy, compensatory hyperfiltration, and increased intraglomerular pressure, leading to podocyte dropout and cytoskeletal damage.\nComprehensive Causes: Spanning familial/genetic risk variants (APOL1), adaptive responses (reduced nephron mass, obesity, hypertension), viral triggers, and drug-induced injuries (lithium, CNIs, bisphosphonates).\nManagement & The GDMT Era: Treatment focuses on reducing glomerular workload rather than immune suppression. Essential pillars include maximum RAAS blockade, SGLT2 inhibitors, GLP-1 receptor agonists, and sparsentan...","thumbnail_url":"https://img.transistorcdn.com/kA5i5pDNY48C1bT4aTakysX4M1kpvKsFppYIkQ0Hgfo/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzQ0NjQyLzE2OTM2/ODM5MzItYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}